Results 101 to 110 of about 427,029 (392)

The effects of time valuation in cancer optimal therapies: a study of chronic myeloid leukemia [PDF]

, 2019
Background The mathematical design of optimal therapies to fight cancer is an important research field in today’s Biomathematics and Biomedicine given its relevance to formulate patient-specific treatments. Until now, however, cancer optimal therapies
Gutiérrez Díez, Pedro José
core   +2 more sources

Management of children and adolescents with chronic myeloid leukemia in blast phase: International pediatric CML expert panel recommendations [PDF]

, 2023
Stephanie Sembill, Maria Ampatzidou, Sonali Chaudhury, Michael Dworzak, Krzysztof Kałwak, Axel Karow, Alexander Kiani, Manuela Krumbholz, Maaike Luesink, Nora Naumann‐Bartsch, Barbara De Moerloose, Michael Osborn, Kirk R. Schultz, Petr Sedláček, Fiorina Giona, C. Michel Zwaan, Hiroyuki Shimada, Birgitta Versluijs, Frédéric Millot, Nobuko Hijiya, Meinolf Suttorp, Markus Metzler   +21 more
openalex   +1 more source

How I treat chronic myeloid leukemia in children and adolescents.

Blood, 2019
Evidence-based recommendations have been established for treatment of chronic myeloid leukemia (CML) in adults treated with tyrosine kinase inhibitors (TKIs), but the rarity of this leukemia in children and adolescents makes it challenging to develop ...
N. Hijiya, M. Suttorp
semanticscholar   +1 more source

Single‐Cell Dissection Reveals Immune Dysregulation After CD5 or CD7‐Directed Chimeric Antigen Receptor T‐Cell Therapy

Advanced Science, EarlyView.
Single‐cell RNA/TCR/BCR sequencing reveals that 5CAR therapy in T‐ALL induces T‐cell exhaustion, reduces EBV‐associated TCRs, lowers TCR/BCR diversity, and increases NK/DC/monocyte activation and function. In contrast, 7CAR therapy reduces multiple pathogen‐associated TCRs, enhances NK cell activation and function, decreases monocyte activation, and ...
Yuechen Luo, Haixiao Zhang, Kaiting Tang, Yiming Wang, Huajiang Dong, Wei Qi, Lingling Shan, Yue Tan, Liping Zhao, Jun Shi, Erlie Jiang, Jing Pan, Xiaoming Feng   +12 more
wiley   +1 more source

The role of peptide and DNA vaccines in myeloid leukemia immunotherapy

Cancer Cell International, 2013
While chemotherapy and targeted therapy are successful in inducing the remission of myeloid leukemia as acute myeloid leukemia (AML) and chronic myeloid leukemia (CML), the disease remains largely incurable.
Lin Chen, Li Yangqiu
doaj   +1 more source

DEL‐1 is an Endogenous Senolytic Protein that Inhibits Senescence‐Associated Bone Loss

Advanced Science, EarlyView.
Senescent bone marrow stromal cells accumulate in the aging bone microenvironment, promoting bone degeneration. DEL‐1, an endogenous secreted protein, acts as a natural senolytic that selectively eliminates these cells. By engaging a β3 integrin/CD73/adenosine/p38 MAPK/BCL‐2 pathway, DEL‐1 counters aging‐related bone loss, revealing promising ...
Jong‐Hyung Lim, Kridtapat Sirisereephap, Hui Wang, Giulia Trimaglio, Kyoung‐Jin Chung, Jonathan Korostoff, Tetsuhiro Kajikawa, Xiaofei Li, Meircurius D.C. Surboyo, Tomoki Maekawa, Triantafyllos Chavakis, George Hajishengallis   +11 more
wiley   +1 more source

Questions and answers about leukemia [PDF]

Leukemia is cancer of the white blood cells. It develops in the bone marrow and spreads into the blood and to other organs. There are several types of leukemia. They are grouped in two ways: by how rapidly the disease develops (acute vs. chronic leukemia)

core  

Analogue peptides for the immunotherapy of human acute myeloid leukemia [PDF]

, 2015
Accepted manuscript. The final publication is available at: http://link.springer.com/article/10.1007%2Fs00262-015-1762-9The use of peptide vaccines, enhanced by adjuvants, has shown some efficacy in clinical trials.
A Driessche Van, A Gros, A Scardino, A Serrano, A Sevko, A Snyder, A Tsuboi, AB Bakker, Aleksandrs Malinovskis, Andrew Mead, AT Cheuk, AW Purcell, B Engels, B Falini, B Maecker, B Maecker, B Uttenthal, BA Guinn, BA Guinn, Barbara-ann Guinn, C Chaise, C Maccalli, CL Slingluff Jr, D Cilloni, D Mason, DA Gross, DE Speiser, DH Chang, DJ Schwartzentruber, E Estey, E Romano, F Ghiringhelli, FS Hodi, G Khan, H Kobayashi, H Ohminami, HJ Kolb, HJ Stauss, I Bellantuono, J Bae, J Bae, J Fourcade, J Greiner, J Greiner, J Kronke, J Pinilla-Ibarz, J Pinilla-Ibarz, JH Sampson, JJ Molldrem, JL Chen, JL Chen, JN Kochenderfer, JS Ko, JW Wells, K Inoue, K Inoue, K Rezvani, K Rezvani, KM Zirlik, L Chan, L Fong, L Gao, LV Ly, M Harndahl, M Kapp, M Subklewe, MA Cheever, MG Warnock, MM Gubin, MR Parkhurst, MS Bijker, N Hardwick, Nicola R. Hardwick, O Christensen, O Hamid, P Brossart, P Bruggen van der, P Keskinen, PG Maslak, PG Maslak, R Cibotti, RA Padua, RF Schlenk, RJ May, S Frankild, S Hofmann, S Narayan, S Ochsenreither, S Pascolo, S Suekane, S Walter, SH Burg van der, SK Singh, SL Topalian, SP Adams, Susanne Hofmann, T Lovgren, U Keilholz, U Sahin, V Bhardwaj, WS Meng, Y Oka, Z Trajanoski   +102 more
core   +2 more sources

Long‐term follow‐up of lower dose dasatinib (50 mg daily) as frontline therapy in newly diagnosed chronic‐phase chronic myeloid leukemia

Cancer, 2019
Dasatinib, a potent Bcr‐Abl tyrosine kinase inhibitor, is approved for the treatment of chronic‐phase chronic myeloid leukemia (CML‐CP) in the frontline and salvage settings. Notable side effects include pleural effusions and myelosuppression.
K. Naqvi, E. Jabbour, Jeffrey Skinner, K. Anderson, S. Dellasala, M. Yilmaz, A. Ferrajoli, P. Bose, P. Thompson, Y. Alvarado, N. Jain, Koichi Takahashi, J. Burger, Z. Estrov, G. Borthakur, N. Pemmaraju, Shilpa Paul, J. Cortes, H. Kantarjian   +18 more
semanticscholar   +1 more source

Safety and Efficacy of Adoptive Transfer of Stem Cell Memory Enriched Virus Specific T Cells against CMV and EBV

Advanced Science, EarlyView.
This study finds that CD8⁺ TSCM cells exhibit superior self‐renewal, differentiation, and antiviral activity. Transcriptome and epigenome analyses highlight MAPK cascade regulation in TSCM cells. In vivo, virus‐specific TSCM cells show enhanced persistence and tumor protection.
Xun‐Hong Cao, Xu‐Ying Pei, Yuan‐Yuan Zhang, Juan Xie, Jing‐Wei Tu, Zhuo‐Jun Liu, Yi‐Yang Ding, Chen‐Hua Yan, Yu‐Hong Chen, Yu Wang, Lan‐Ping Xu, Xiao‐Hui Zhang, Xiao‐Jun Huang, Xiang‐Yu Zhao   +13 more
wiley   +1 more source